Serum cholinesterase is an excellent biomarker of liver cirrhosis

Ramachandran, Jeyamani

doi:10.7869/tg.158

Cited by 54 publications

(43 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in agreement with a study conducted by Ramachandran et al (2014) who found median serum ChE in cirrhotics was 1590 IU/L (110 to 8143) compared to 7886 IU/L (2022-21673) in controls. Determining serum albumin levels and assessing prothrombin time are often considered "tests of liver function" (Bonis et al, 1999;Kamath et al, 2001;Kamath et al, 2001).…”

Section: Discussionsupporting

confidence: 93%

“…These findings provide evidence for a limitation in the use of cholinesterase as a liver function test. This is in agreement with Ramachandran et al (2014) who found that correlation coefficient between cholinesterase and albumin was -0.67, and Lee (2012) who cited that albumin has been widely used in patients with cirrhosis in an attempt to improve circulatory and renal functions. Nakamura et al (2014) demonstrated that the administration of albumin significantly increased the serum levels of albumin in patients with liver cirrhotic disease.…”

Section: Parametersupporting

confidence: 90%

“…This could be as a result of liver cirrhosis that directly affects its function leading to deficient liver production. This is in agreement with findings by Ramachandran et al (2014). The synthetic function of the liver is reflected by the levels of serum cholinesterase (ChE) which is synthesised by hepatocytes (Matsuzaki et al, 1980;Strahl and Maier, 2006).…”

Section: Discussionsupporting

confidence: 79%

See 2 more Smart Citations

Serum cholinesterase as liver function test in cirrhotic patients at Soba Teaching hospital, Khartoum, Sudan

Mohamed¹,

Amanullah²,

Amanvermez³

et al. 2017

Int Res J Med Med Sci

View full text Add to dashboard Cite

It is suggested that plasma cholinesterase level is affected by liver cirrhosis due to hepatocyte injury. The objective of this study was to determine cholinesterase values in association with albumin and prothrombin during both the compensated and decompensated stages in cirrhotic patients. A total of 150 consecutive episodes of liver cirrhotic patients, aged (68.9 ± 10 years) admitted to the hospital between June 2015 and December 2015 were studied. They were classified into subgroups according to severity and the stages of disease into group A (compensated stage) and group B (decompensated stage), each containing 75 patients. Fifty apparently healthy participants aged 64.5 ± 13 years were recruited as controls. Blood samples were drawn and targeted parameters were assessed using commercial kits according to the manufacturer's guide. SPSS package was used for data analysis. There was a significant difference in the mean serum cholinesterase activity, albumin level and prothrombin time of cases and controls. The mean serum cholinesterase value of compensated cirrhotic patients was 3143.83 ± 1583.44 IU/L and it was significantly higher (p = 0.000) than that of decompensated cirrhotic patients (1895.32 ± 531.79 IU/L). There was a strong negative correlation between serum cholinesterase activity and prothrombin time (r = -0.580, p = 0.000) and a strong positive correlation between serum cholinesterase activity and albumin concentration (r = 0.617, p = 0.00). The results conclude that, cholinesterase level reflects liver cell conditions wherein low levels indicate hepatocellular damage. In addition, its levels are stable and not easily affected by medications that are given for cirrhotic patients thus, can be used as a marker for the diagnosis and prognosis of liver damage along with prothrombin time and albumin.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Parametersupporting

confidence: 90%

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

Serum cholinesterase as liver function test in cirrhotic patients at Soba Teaching hospital, Khartoum, Sudan

Mohamed¹,

Amanullah²,

Amanvermez³

et al. 2017

Int Res J Med Med Sci

View full text Add to dashboard Cite

show abstract

“…William Burnett also found serum cholinesterase is useful both as a liver function test and in the diagnosis of jaundice 19. Ramachandran et al found Median serum ChE in cirrhotics was 1590 IU/L (110-8143) compared to controls 7886IU/L (2022-21673), p<0.001. Serum ChE levels below 3506 had a 98.7% sensitivity and 80.3% specificity in predicting cirrhosis found serum ChE is an excellent biomarker of cirrhosis with good sensitivity and specificity 20 .…”

Section: Discussionmentioning

confidence: 91%

Serum cholinesterase as diagnostic marker of liver disease

Gokani

Jadav

Shaikh³

et al. 2014

Int J of Biomed & Adv Res

View full text Add to dashboard Cite

“…Even if this is not true, high pChE is almost certainly associated with low-grade inflammation, and it should be avoided in AD patients. Conversely, low pChE should be avoided in AD patients because because low-grade pChE is related with liver dysfunction [19]. Therefore, pChE should be maintained within an optimal therapeutic level that is neither too high nor too low, which could be achieved by rational therapy.…”

Section: Resultsmentioning

confidence: 99%

Plasma Cholinesterase Activity in Alzheimer's Disease

et al. 2015

View full text Add to dashboard Cite

Cholinesterase inhibitors (ChEIs) are not allowed to be prescribed in combination, which means that we need to select 1 of 3 ChEIs for use in a patient with Alzheimer's disease (AD). However, there is no quantitative analysis on the differences between these agents. In this article, we propose that plasma cholinesterase activity (pChE) could be used as the standard for differentiating between rivastigmine (Riv) and donepezil (Don) in the management of AD. To date, we have treated 6 patients with Riv 18 mg and 5 patients with Don 5 mg. The pChE is related to low-grade inflammation associated with AD, diabetes mellitus and lipid metabolic dysfunction. Moreover, low pChE is related to liver dysfunction. The pChE must be kept under control. We speculated that Riv is the most appropriate therapy for patients with relatively high pChE, whereas Don is best reserved for those AD patients with relatively low pChE.

show abstract

Serum cholinesterase is an excellent biomarker of liver cirrhosis

Abstract: Background: Serum cholinesterase (ChE) is an enzyme synthesised by hepatocytes and its

Cited by 54 publications

References 13 publications

Serum cholinesterase as liver function test in cirrhotic patients at Soba Teaching hospital, Khartoum, Sudan

Serum cholinesterase as liver function test in cirrhotic patients at Soba Teaching hospital, Khartoum, Sudan

Serum cholinesterase as diagnostic marker of liver disease

Plasma Cholinesterase Activity in Alzheimer's Disease

Contact Info

Product

Resources

About